View in EDS

Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity.

Saved in:
Bibliographic Details
Title: Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity.
Authors: Susanto O; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia., Gruber E; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Wun CM; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Franich RL; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Ma X; Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia., Sabouri-Thompson Z; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia., Porter ZJ; Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia., Murray HC; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, Australia.; Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, Australia., Cluse LA; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Maher B; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.; Monash Haematology, Monash Health, Clayton, Australia., Brasacchio D; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia., Martin BP; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Fraser PJ; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Nikolic I; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Australia., Mir Arnau G; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Molecular Genomics Core, Peter MacCallum Cancer Centre, Melbourne, Australia., Sandow JJ; Walter and Eliza Hall Institute, Parkville, Australia.; Department of Medical Biology, University of Melbourne, Parkville, Australia., Simpson KJ; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, Australia., Verrills NM; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, Australia.; Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, Australia., Johnstone RW; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Thompson PE; Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia., Kats LM; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Shortt J; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Monash Haematology, Monash Health, Clayton, Australia.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2026 Mar 02; Vol. 25 (3), pp. 416-434.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41185616
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Susanto+O%22">Susanto O</searchLink>; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.<br /><searchLink fieldCode="AU" term="%22Gruber+E%22">Gruber E</searchLink>; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Wun+CM%22">Wun CM</searchLink>; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Franich+RL%22">Franich RL</searchLink>; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Ma+X%22">Ma X</searchLink>; Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Sabouri-Thompson+Z%22">Sabouri-Thompson Z</searchLink>; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.<br /><searchLink fieldCode="AU" term="%22Porter+ZJ%22">Porter ZJ</searchLink>; Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Murray+HC%22">Murray HC</searchLink>; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, Australia.; Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, Australia.<br /><searchLink fieldCode="AU" term="%22Cluse+LA%22">Cluse LA</searchLink>; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Maher+B%22">Maher B</searchLink>; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.; Monash Haematology, Monash Health, Clayton, Australia.<br /><searchLink fieldCode="AU" term="%22Brasacchio+D%22">Brasacchio D</searchLink>; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.<br /><searchLink fieldCode="AU" term="%22Martin+BP%22">Martin BP</searchLink>; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Fraser+PJ%22">Fraser PJ</searchLink>; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Nikolic+I%22">Nikolic I</searchLink>; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Mir+Arnau+G%22">Mir Arnau G</searchLink>; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Molecular Genomics Core, Peter MacCallum Cancer Centre, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Sandow+JJ%22">Sandow JJ</searchLink>; Walter and Eliza Hall Institute, Parkville, Australia.; Department of Medical Biology, University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Simpson+KJ%22">Simpson KJ</searchLink>; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Verrills+NM%22">Verrills NM</searchLink>; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, Australia.; Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, Australia.<br /><searchLink fieldCode="AU" term="%22Johnstone+RW%22">Johnstone RW</searchLink>; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Thompson+PE%22">Thompson PE</searchLink>; Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Kats+LM%22">Kats LM</searchLink>; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Shortt+J%22">Shortt J</searchLink>; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Monash Haematology, Monash Health, Clayton, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2026 Mar 02; Vol. 25 (3), pp. 416-434.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41185616
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-25-0306
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 416
    Titles:
      – TitleFull: Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Susanto O
      – PersonEntity:
          Name:
            NameFull: Gruber E
      – PersonEntity:
          Name:
            NameFull: Wun CM
      – PersonEntity:
          Name:
            NameFull: Franich RL
      – PersonEntity:
          Name:
            NameFull: Ma X
      – PersonEntity:
          Name:
            NameFull: Sabouri-Thompson Z
      – PersonEntity:
          Name:
            NameFull: Porter ZJ
      – PersonEntity:
          Name:
            NameFull: Murray HC
      – PersonEntity:
          Name:
            NameFull: Cluse LA
      – PersonEntity:
          Name:
            NameFull: Maher B
      – PersonEntity:
          Name:
            NameFull: Brasacchio D
      – PersonEntity:
          Name:
            NameFull: Martin BP
      – PersonEntity:
          Name:
            NameFull: Fraser PJ
      – PersonEntity:
          Name:
            NameFull: Nikolic I
      – PersonEntity:
          Name:
            NameFull: Mir Arnau G
      – PersonEntity:
          Name:
            NameFull: Sandow JJ
      – PersonEntity:
          Name:
            NameFull: Simpson KJ
      – PersonEntity:
          Name:
            NameFull: Verrills NM
      – PersonEntity:
          Name:
            NameFull: Johnstone RW
      – PersonEntity:
          Name:
            NameFull: Thompson PE
      – PersonEntity:
          Name:
            NameFull: Kats LM
      – PersonEntity:
          Name:
            NameFull: Shortt J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 03
              Text: 2026 Mar 02
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1